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Safety and efficacy of 
the Russian COVID-19 
vaccine: more 
information needed
We read with great interest the results 
presented by Denis Logunov and 
colleagues on the safety and efficacy of 
a Russian vaccine for COVID-19.1
Although the study results are 
potentially significant, we have several 
concerns, which, due to the accelerated 
distribution of the vaccine to the 
population, we described in an open 
letter signed by us and by several other 
colleagues who share our concerns. 
In particular, after finding multiple 
repeated patterns in the data, we 
realised that the numerical values for 
each studied individual are missing. 
Such detailed information is needed 
to understand if different groups 
or individuals show identical or 
very similar patterns of data and to 
understand, in a group with identical 
or very similar percentages of CD4+ 
and CD8+ T cells at time 0, the degree 
of overlap of these two independent, 
continuous variables.
As for comparing post-vaccination 
immunity with antibody response to 
infection with severe acute respiratory 
syndrome coronavirus 2, it is unclear 
how many of the 4187 individuals 
from Moscow who had recovered from 
COVID-19 were included in the analysis 
of receptor binding domain-specific 
and neutralising antibodies,1 and 
how they match to the experimental 
cohorts regarding, for example, time 
after vaccination and natural infection, 
respectively. 
We also believe the individual 
raw FACS data used for figure 3 are 
needed to verify the actual overlap of 
CD4+ and CD8+ T cell proliferation 
percentages that are apparent from 
the presented graphs.
We note the statement “Between 
June 18 and Aug 3, 2020, we enrolled 
76 participants to the two studies (38 in 
each study)”.1 However, according to 
the published protocols for these 
two clinical trials (NCT04437875 
and NCT04436471), the primary 
completion date of both studies was 
Aug 3, 2020; the enrolment should 
have been completed well before 
Aug 3, 2020, to have antibody data 
for all participants at 42 days. In the 
protocol for NCT04437875, we also 
noted the statement “Throughout the 
inpatient observation and the follow-
up period (180 days) of visits during 
the entire study, safety information 
will be collected.” This implies that the 
entire study was not completed when 
the Article was published by The Lancet, 
and safety data were partial.
It is also not clear whether the study 
is a phase 1/2, with a phase 2 starting 
“no earlier than 5 days”1 after the 
phase 1, as reported in the Article, or 
a two-stage phase 1 study, as per the 
published protocols.
We feel that a detailed answer and 
rendering the actual data available 
would considerably strengthen the 
significance of the study findings.
EB is the owner of Resis Srl. All other authors declare 
no competing interests.
*Enrico Bucci, Konstantin Andreev, 
Anders Björkman, 
Raffaele Adolfo Calogero, 
Ernesto Carafoli, Piero Carninci, 
Paola Castagnoli, Andrea Cossarizza, 
Cristina Mussini, Philippe Guerin, 
Brian Lipworth, Gianluca Sbardella, 
Teresa Stocki, Loretta Tuosto, 
Christoffer van Tulleken, 
Antonella Viola
enrico.bucci@resis-srl.com
Sbarro Health Research Organization, Temple 
University, Philadelphia, PA, USA (EB); Resis Srl, 
10010 Samone, Italy (EB); Northwestern 
University, Evanston, IL, USA (KA); Howard Hughes 
Medical Institute, Chevy Chase, MD, USA (KA); 
Karolinska Institutet, Stockholm, Sweden (AB); 
University of Turin, Tornio, Italy (RAC); Accademia 
Nazionale dei Lincei, Rome, Italy (EC); RIKEN 
Center for Integrative Medical Sciences, Yokohama, 
Japan (PCar); Toscana Life Sciences Foundation, 
Siena, Italy (PCas); University of Modena and 
Reggio Emilia, Modena, Italy (AC, CM); University 
of Oxford, Oxford, UK (PG); University of Dundee, 
Dundee, UK (BL); University of Salerno, Fisciano, 
Italy (GS); Leeds Teaching Hospitals National 
Health Service Trust, Leeds, UK (TS); Sapienza 
University of Rome, Rome, Italy (LT); University 
College London, London, UK (CvT); and University 
of Padua, Padua, Italy (AV)
1 Logunov DY, Dolzhikova I V, Zubkova O V, et al. 
Safety and immunogenicity of an rAd26 and 
rAd5 vector-based heterologous prime-boost 
COVID-19 vaccine in two formulations: 
two open, non-randomised phase 1/2 studies 




September 18, 2020 
https://doi.org/10.1016/ 
S0140-6736(20)31960-7
For the open letter see 
https://cattiviscienziati.
com/2020/09/07/note-of-
concern/
